The FDA isn’t afraid to yank a disappointing drug
The FDA is rescinding its approval of a blood cancer treatment from the Swedish firm Oncopeptides. It's the agency’s first exercise of a new authority that allows regulators to more…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, everyone. Damian here with a look at some renewed interest in a yesteryear biotech craze, news of an FDA flex, and a dive into the science of vaccinology.
What's Your Reaction?
